BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Bogdana Schmidt
Absolutely. And then just getting to Sunrise One, which was obviously in the non-muscle invasive space, they also showed incredibly promising results, 83% with just TAR 200 alone, which I think is really great. I'm personally, as a surgeon, a big believer in TAR. intravesical treatments for intravesical-only non-muscle invasive disease.
0
💬
0
Comments
Log in to comment.
There are no comments yet.